Scholarlink

Background <p>Methotrexate (MTX) is a cornerstone of systemic therapy for treating moderate to severe psoriasis. It can be given orally or subcutaneously (SC). SC MTX offers higher bioavailability and more predictable exposure. However, head-to-head clinical evidence is limited. We systematically compared the efficacy and safety of SC and oral MTX to inform route selection.</p> Methods <p>Building upon this background, we conducted a systematic review and network meta-analysis with random effects. Randomized controlled trials (RCTs) were identified from major databases up to 2025. Ten RCTs met the inclusion criteria. Outcomes included change in Psoriasis Area and Severity Index (PASI) from baseline, PASI 50/75/90/100 responses, and adverse events. Treatments were ranked using the Surface Under the Cumulative Ranking curve (SUCRA) probabilities.</p> Results <p>Our review and analysis showed that, across analyses, subcutaneous methotrexate (SC MTX) ranked higher than oral methotrexate (oral MTX) for PASI75 (SUCRA 0.98 vs. 0.52), PASI90 (0.98 vs. 0.39), and PASI100 (0.93 vs. 0.50). Subcutaneous methotrexate increased the odds of PASI75 (OR 5.48, 95% CI 2.53–11.85) and PASI90 (OR 3.33, 95% CI 1.09–10.13). Oral methotrexate slightly favored PASI50. Neither formulation reached significance for PASI100. Mean PASI reduction did not differ directly, despite superior rankings for subcutaneous methotrexate. Subcutaneous methotrexate was also associated with fewer adverse events and lower rates of discontinuation.</p> Conclusion <p>SC MTX more effectively achieves PASI thresholds and is better tolerated, supporting its use as the preferred systemic treatment for moderate to severe psoriasis.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Comparative efficacy and safety of oral versus subcutaneous methotrexate in the treatment of psoriasis: a systematic review, pairwise and network meta-analysis with CINeMA and GRADE assessment

  • 期刊论文

  • 发表日期：

    2025年11月18日

查看全文
  • Nesreen Alhamwi,
  • Ahmad Omar Saleh,
  • Bara M. Hammadeh,
  • Osama M. Aldeeb,
  • Abdallah Shawwa,
  • Layan Lafi,
  • Lina Elkadri,
  • Ayat Mohsen,
  • Noor J. Mansour,
  • Aseel Rizik,
  • Zeina Al Halasa,
  • Ammar Aljarrah

摘要

Background

Methotrexate (MTX) is a cornerstone of systemic therapy for treating moderate to severe psoriasis. It can be given orally or subcutaneously (SC). SC MTX offers higher bioavailability and more predictable exposure. However, head-to-head clinical evidence is limited. We systematically compared the efficacy and safety of SC and oral MTX to inform route selection.

Methods

Building upon this background, we conducted a systematic review and network meta-analysis with random effects. Randomized controlled trials (RCTs) were identified from major databases up to 2025. Ten RCTs met the inclusion criteria. Outcomes included change in Psoriasis Area and Severity Index (PASI) from baseline, PASI 50/75/90/100 responses, and adverse events. Treatments were ranked using the Surface Under the Cumulative Ranking curve (SUCRA) probabilities.

Results

Our review and analysis showed that, across analyses, subcutaneous methotrexate (SC MTX) ranked higher than oral methotrexate (oral MTX) for PASI75 (SUCRA 0.98 vs. 0.52), PASI90 (0.98 vs. 0.39), and PASI100 (0.93 vs. 0.50). Subcutaneous methotrexate increased the odds of PASI75 (OR 5.48, 95% CI 2.53–11.85) and PASI90 (OR 3.33, 95% CI 1.09–10.13). Oral methotrexate slightly favored PASI50. Neither formulation reached significance for PASI100. Mean PASI reduction did not differ directly, despite superior rankings for subcutaneous methotrexate. Subcutaneous methotrexate was also associated with fewer adverse events and lower rates of discontinuation.

Conclusion

SC MTX more effectively achieves PASI thresholds and is better tolerated, supporting its use as the preferred systemic treatment for moderate to severe psoriasis.